(Adnkronos) - EMA opinion marks the first qualification of a digital outcome measure for use as a primary endpoint in pivotal drug trials
SV95C is an objective, real-world digital ambulation measure of top performance, informing more confident treatment decision-making and streamlining drug development, with potential to shorten